What is the recommended aspirin (acetylsalicylic acid) dosage after surgical atrial septal defect closure?

Aspirin Dosing After Surgical ASD Closure

Critical Distinction: Your Question Addresses Surgical Closure, Not Device Closure

The available guidelines specifically address transcatheter (device) closure of atrial septal defects, not open surgical closure. The American Heart Association guidelines provide clear recommendations for device closure but do not establish specific aspirin protocols for traditional surgical repair 1.

Evidence-Based Recommendations

For Device Closure (Not Your Question, But Best Available Evidence):

• Low-dose aspirin for at least 6 months is the standard recommendation after transcatheter ASD device closure 1
• The typical dosing referenced is "low-dose aspirin" (commonly 81-100 mg daily in adults) 1
• In pediatric patients undergoing device closure, weight-based dosing is used, though specific mg/kg recommendations are not detailed in the guidelines 1

For Surgical Closure (Your Actual Question):

Based on the absence of guideline recommendations for surgical ASD closure and extrapolating from device closure protocols, low-dose aspirin (81-100 mg daily in adults) for 6 months represents the most reasonable approach, though this is not formally established in guidelines.

Key Evidence Gaps:

• No Class I or II recommendations exist specifically for aspirin after surgical ASD repair 1
• One pediatric study examined prophylactic aspirin (20-50 mg/kg/day for 1-6 weeks) after surgical ASD closure and found it did not reduce postpericardiotomy syndrome, though this addresses a different outcome than thromboprophylaxis 2
• The surgical closure context differs fundamentally from device closure because there is no foreign body requiring endothelialization 1

Clinical Reasoning

Why Surgical Closure May Not Require the Same Protocol:

• Device closure requires thromboprophylaxis until complete endothelialization occurs (approximately 6 months) 1
• Surgical repair involves direct tissue closure without implanted hardware, eliminating the primary thrombotic risk 1
• The 6-month aspirin protocol for devices is specifically designed to prevent device-related thrombosis, not surgical site complications 1

Practical Approach for Surgical ASD Closure:

In the absence of specific guidelines, consider:

• Low-dose aspirin (81-100 mg daily) for 6-8 weeks post-operatively as general cardiac surgery thromboprophylaxis
• Extend to 6 months if there are additional risk factors (history of stroke, thrombophilic disorders, incomplete closure, or residual shunt) 1
• No aspirin beyond standard post-operative protocols may be appropriate for uncomplicated surgical repairs in low-risk patients

Important Caveats

High-Risk Scenarios Requiring Extended Therapy:

• Patients with residual shunts after surgical repair should receive prolonged thromboprophylaxis (beyond 6 months) due to ongoing paradoxical embolus risk 1
• History of stroke or known thrombophilic disorders warrants adapted antithrombotic strategies 1
• Older adults or those with additional cardiovascular risk factors may benefit from extended therapy 1

Dual Antiplatelet Therapy:

• Combination aspirin plus clopidogrel is mentioned for older patients after device closure but carries a Class IIb recommendation (may be considered) 1
• This is not standard for surgical closure and should be reserved for specific high-risk scenarios
• Recent evidence suggests dual therapy does not provide additional benefit over aspirin alone for device closure 3, 4

Bottom Line

The evidence specifically addresses device closure, not surgical closure of ASDs. For surgical repair, standard post-cardiac surgery aspirin protocols (81-100 mg daily for 6-8 weeks) are reasonable, with extension to 6 months reserved for patients with residual shunts or other high-risk features. The robust 6-month aspirin recommendation applies definitively only to transcatheter device closure 1.